-
-
-
-
-
-
-
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
-
-
-
-
-
-
-
Teva Pharma (TEVA) Settles Price Fixing Charges With DOJ
-
-
-
-
-
-
-
Teva Launches New “Pivot to Growth” Strategy
-
-
-
-
-
-
-
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophren
-
-
-
-
-
-
-
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
-
-
-
-
-
-
-
Teva Pharma (TEVA) Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
-
-
-
-
-
-
-
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

